Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 125

Sort by

Sort Order Select

Journal Articles

Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies

Anthony R. Mato, MDMSCE, Lindsey E. Roeker, MD, Toby A. Eyre, MBBChir, MRCP, Ryan Jacobs, MD, Brian T. Hill, MD, Nicole Lamanna, MD, Danielle M. Brander, MD, Mazyar Shadman, MD, Chaitra Ujjani, MD, Maryam Yazdy, MD, Guilherme Fleury Perini, MD, Javier Pinilla Ibarz, MD PhD, Jacqueline C Barrientos, MD, Alan Skarbnik, MD, Pallawi Torka, MD, Jeffrey J Pu, MD PhD, John M. Pagel, MD PhD DSc, Satyen Gohil, BSc, MBBS, MRCP, FRCPath, Bita Fakhri, MDMPH, Michael Y. Choi, MD, Catherine C. Coombs, MD, Joanna Rhodes, MD, Paul M. Barr, MD, Craig A. Portell, MD, Helen Parry, MB ChB, MRCP, PhD, Christine Ann Garcia, MD MPH, Kate J Whitaker, BA, Allison M. Winter, MD, Andrea Sitlinger, MD, Sirin Khajavian, MD, Ariel F Grajales-Cruz, MD, Krista Isaac, DO, MS, Pratik Shah, Othman S. Akhtar, MD, Rachael Pocock, MD, Kentson Lam, MD PhD, Timothy J Voorhees, MD, Stephen J. Schuster, MD, Thomas David Rodgers, MD, Nicolas Martinez-Calle, MD MSc, Talha Munir, MD, Erica B Bhavsar, BS, Neil Bailey, MSc, Jason C. Lee, MD, Hanna Weissbrot, BS, Chadi Nabhan, MDMBA, FACP, Julie Goodfriend, Amber C. King, PharmD, BCOP, Andrew D. Zelenetz, MD PhD, Colleen Dorsey, BSN, RN, Kayla Bigelow, Bruce D. Cheson, MD, Christopher P Fox, MBChB(Hons), MRCP, FRCPath, PhD, John N. Allan, MD

Blood (2019) 134 (Supplement_1): 502.

https://doi.org/10.1182/blood-2019-123747

Published: 2019

Journal Articles

Increased Release of Soluble MD-2 in Sickle Cell Disease and Its Role in Pro-Inflammatory Signaling in Endothelial Cells

Ping Zhang, PhD, John D Belcher, PhD, Julia Nguyen, Fuad Abdulla, Gregory M Vercellotti, MD

Blood (2019) 134 (Supplement_1): 208.

https://doi.org/10.1182/blood-2019-122912

Published: 2019

Journal Articles

Identification of Tractable Drug-like eIF4Al Inhibitors with Potent Anti-Tumor Activity

Tyler A. Cunningham, BS, Derek Essegian, BS, MS, Stephan Schürer, PhD, Jonathan H. Schatz, MD

Blood (2019) 134 (Supplement_1): 5760.

https://doi.org/10.1182/blood-2019-130494

Published: 2019

Journal Articles

Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL

Shanye Yin, PhD, Salma Parvin, PhD, Elisa Ten Hacken, PhD, Rebecca Valentin, MD, Heather Joyal, Laura Z. Rassenti, PhD, Emanuela M. Ghia, PhD, Thomas J. Kipps, MD PhD, Donna S Neuberg, ScD, Lili Wang, MD PhD, Matthew S. Davids, MD, Ruben D. Carrasco, MD PhD, Anthony G. Letai, MD PhD, Catherine J. Wu, MD

Blood (2019) 134 (Supplement_1): 4281.

https://doi.org/10.1182/blood-2019-127293

Published: 2019

Journal Articles

Outcomes of Follicular Lymphoma (FL) with Early Progression (EP): Does Choice of Second Line Therapy Impact the Course of Disease?

Ahmad Hanif, MD, Sumera Khan, MSc, MD, Pallawi Torka, MD, Kris Attwood, PhD MS, Francisco J. Hernandez-Ilizaliturri, MD

Blood (2018) 132 (Supplement 1): 4156.

https://doi.org/10.1182/blood-2018-99-117908

Published: 2018

Journal Articles

Longitudinal High-Throughput T Cell Repertoire Profiling of Chronic Lymphocytic Leukemia Patients Under Different Types of Treatment: Implications for Combination Strategies

Anna Vardi, MD PhD, Elisavet Vlachonikola, Nikolaos Ioannou, PhD MSc, BSc, Fotis Psomopoulos, Konstantia Kotta, Despoina Papazoglou, BSc, Maria Kotouza, Evangelia Koravou, Chrysi Galigalidou, Katerina Gemenetzi, Kostas Pasentsis, Michalis Iskas, Niki Stavroyianni, Achilles Anagnostopoulos, Alan G. Ramsay, BSc, MSc, PhD, Kostas Stamatopoulos, MD PhD, Anastasia Hadzidimitriou, PhD

Blood (2018) 132 (Supplement 1): 4400.

https://doi.org/10.1182/blood-2018-99-118006

Published: 2018

Journal Articles

Computational Identification of Tractable Drug-like Inhibitors of eIF4A1

Derek Essegian, BS, MS, Tyler A. Cunningham, BS, Jonathan H. Schatz, MD, Stephan Schurer, PhD

Blood (2018) 132 (Supplement 1): 5802.

https://doi.org/10.1182/blood-2018-99-116829

Published: 2018

Journal Articles

Rational Targeting of Cellular Cholesterol in Diffuse Large B-Cell Lymphoma (DLBCL) Enabled By Functional Lipoprotein Nanoparticles and the B Cell Receptor Inhibitor Ibrutinib: A Therapeutic Strategy Dependent on Cell of Origin (COO)

Jonathan Rink, PhD, Osman Cen, PhD, Kaylin Marie McMahon, PhD, Sol Misener, BS, Shuo Yang, PhD, Colby Shad Thaxton, MD PhD, Leo I. Gordon, MD

Blood (2017) 130 (Supplement 1): 576.

https://doi.org/10.1182/blood.V130.Suppl_1.576.576

Published: 2017

Journal Articles

IL6 Signaling Regulates Embryonic Hematopoietic Stem Cell Emergence

He Huang, MD, Honghu Lee, graduate student, Ruxiu Tie, PhD, Binsheng Wang, postdoctor, Shuyang Cai, graduate student, Xue Lee, graduate student, Huafang Wang, PhD, Mei Liu, graduate student, Yingying Ding, graduate student

Blood (2017) 130 (Supplement 1): 1136.

https://doi.org/10.1182/blood.V130.Suppl_1.1136.1136

Published: 2017

Journal Articles

The Clinical BET Inhibitor, GS-5829, Is Active Against Chronic Lymphocytic Leukemia As Single Agent and in Combination with B-Cell Receptor Signaling Inhibitors

Ekaterina Kim, PhD, Elisa Ten Hacken, PhD, Astrid Clarke, PhD, Michael J. Keating, MD, William G Wierda, MD PhD, Alessandra Ferrajoli, MD, Nitin Jain, MD, Philip A Thompson, MBBS, Zeev Estrov, MD, Jan A. Burger, MD PhD

Blood (2017) 130 (Supplement 1): 3844.

https://doi.org/10.1182/blood.V130.Suppl_1.3844.3844

Published: 2017

Journal Articles

Single-Cell Drug Profiling Reveals Maturation Stage-Dependent Drug Responses in AML

Heikki Kuusanmäki, MSc, Maija Leppä, BSc, Mika Kontro, MD, Olli Dufva, BSc, Debashish Deb, MSc, Bhagwan Yadav, PhD, Satu Mustjoki, MDPhD, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2017) 130 (Supplement 1): 3821.

https://doi.org/10.1182/blood.V130.Suppl_1.3821.3821

Published: 2017

Journal Articles

The Marine Natural Compound Elatol Is a Novel Protein Translation Inhibitor with Potent Activity Against Aggressive Non-Hodgkin Lymphomas

Tara Peters, BA, Joseph Tillotson, PhD, Sarah C Wilmore, BSc, Alison Yeomans, PhD, Graham Packham, PhD, Eli Chapman, PhD, Jonathan H. Schatz, MD, Lingxiao Li, PhD

Blood (2017) 130 (Supplement 1): 4112.

https://doi.org/10.1182/blood.V130.Suppl_1.4112.4112

Published: 2017

Journal Articles

Midostaurin Shows Efficacy in Refractory Multiple Myeloma with TP53 Mutation and Elevated Expression of NTRK1, NTRK3 and AURKA

Muntasir M Majumder, MSc, BPharm, David Tamborero, PhD, Pekka Anttila, Raija Helena Silvennoinen, MD, Samuli Eldfors, MSc, Juha Lievonen, Ashwini Kumar, MRes, Alun Parsons, Minna Suvela, MSC, Esa Jantunen, Kimmo Porkka, MD PhD, Caroline A Heckman, PhD

Blood (2017) 130 (Supplement 1): 4412.

https://doi.org/10.1182/blood.V130.Suppl_1.4412.4412

Published: 2017

Journal Articles

External Stimuli Modulate EZH2 Expression in Chronic Lymphocytic Leukemia. Rationale and Evidence for Synergistic Anti-Tumor Effects of B Cell Signaling and EZH2 Inhibitors

Elisavet Chartomatsidou, Stavroula Ntoufa, Konstantia Kotta, Marianna Akritidou, Theoni Trangas, Niki Stavroyianni, Achilles Anagnostopoulos, Richard Rosenquist, MD PhD, Paolo Ghia, Nikos Papakonstantinou, Kostas Stamatopoulos

Blood (2017) 130 (Supplement 1): 4295.

https://doi.org/10.1182/blood.V130.Suppl_1.4295.4295

Published: 2017

Journal Articles

Redundant JAK, SRC and PI3 Kinase Signaling Pathways Regulate Cell Survival in Human Ph-like ALL Cell Lines and Primary Cells

Christian Hurtz, PhD, Sarah K Tasian, MD, Gerald Wertheim, MD, PhD, Bruce Ruggeri, Matthew C. Stubbs, Alexander E. Perl, MD, Martin Carroll, MD

Blood (2017) 130 (Supplement 1): 717.

https://doi.org/10.1182/blood.V130.Suppl_1.717.717

Published: 2017

Journal Articles

Megakaryocytic TGFβ1 Partitions Hematopoiesis into Amplifying Stem and Progenitor Cells and Maturing Effector Cells

Silvana Di Giandomenico, PhD, Pouneh Kermani, PhD, Nicole Molle, BS, Mia Yabut, BS, Fabienne Brenet, PhD, Shahin Rafii, MD, Joseph Scandura, MDPhD

Blood (2017) 130 (Supplement 1): 81.

https://doi.org/10.1182/blood.V130.Suppl_1.81.81

Published: 2017

Journal Articles

Notch Signaling Controls Drug Response in B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Paul Takam Kamga, BSc, MSc, Giada Dal Collo, MSc, Martina Midolo, PhD, Annalisa Adamo, MSc, Alessandro Gatti, MSc, Roberta Carusone, PhD, Elda Mimiola, MDPhD, Angela Mercuri, MSc, Massimiliano Bonifacio, MD, Mauro Krampera, MD PhD

Blood (2017) 130 (Supplement 1): 2535.

https://doi.org/10.1182/blood.V130.Suppl_1.2535.2535

Published: 2017

Journal Articles

Differential Impact of Signaling Inhibitor Treatment Versus Standard Chemoimmunotherapy on Chronic Lymphocytic Leukemia T Cells: Clinical Implications

Anna Vardi, MD PhD, Elisavet Vlachonikola, Evangelia Koravou, Chrysi Galigalidou, Katerina Gemenetzi, Evangelia Stalika, Andreas Agathangelidis, Michalis Iskas, Niki Stavroyianni, Achilles Anagnostopoulos, Kostas Stamatopoulos, Anastasia Hadzidimitriou

Blood (2017) 130 (Supplement 1): 2999.

https://doi.org/10.1182/blood.V130.Suppl_1.2999.2999

Published: 2017

Journal Articles

Altered Peripheral Immune Phenotypes in Mantle Cell Lymphoma Survivors

Tanaya Shree, MD PhD, Sangeeta Kowli, PhD, Holden T. Maecker, PhD, Ronald Levy, MD

Blood (2017) 130 (Supplement 1): 2759.

https://doi.org/10.1182/blood.V130.Suppl_1.2759.2759

Published: 2017

Journal Articles

Increased Risk of Toxicity with Novel PI3K Delta Inhibitor Combinations Compared with Standard Use in Non-Hodgkin Lymphoma Patients

Annalynn Williams, MS, Elizabeth Baloga, Andrea Baran, MS, Margaret Helber, PharmD, Jeremiah Moore, PharmD, Carla Casulo, MD, Patrick M. Reagan, MD, Jonathan W. Friedberg, MD, Clive S Zent, MD, Paul M. Barr, MD

Blood (2017) 130 (Supplement 1): 4050.

https://doi.org/10.1182/blood.V130.Suppl_1.4050.4050

Published: 2017

NARROW

Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies

Increased Release of Soluble MD-2 in Sickle Cell Disease and Its Role in Pro-Inflammatory Signaling in Endothelial Cells

Identification of Tractable Drug-like eIF4Al Inhibitors with Potent Anti-Tumor Activity

Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL

Outcomes of Follicular Lymphoma (FL) with Early Progression (EP): Does Choice of Second Line Therapy Impact the Course of Disease?

Longitudinal High-Throughput T Cell Repertoire Profiling of Chronic Lymphocytic Leukemia Patients Under Different Types of Treatment: Implications for Combination Strategies

Computational Identification of Tractable Drug-like Inhibitors of eIF4A1

Rational Targeting of Cellular Cholesterol in Diffuse Large B-Cell Lymphoma (DLBCL) Enabled By Functional Lipoprotein Nanoparticles and the B Cell Receptor Inhibitor Ibrutinib: A Therapeutic Strategy Dependent on Cell of Origin (COO)

IL6 Signaling Regulates Embryonic Hematopoietic Stem Cell Emergence

The Clinical BET Inhibitor, GS-5829, Is Active Against Chronic Lymphocytic Leukemia As Single Agent and in Combination with B-Cell Receptor Signaling Inhibitors

Single-Cell Drug Profiling Reveals Maturation Stage-Dependent Drug Responses in AML

The Marine Natural Compound Elatol Is a Novel Protein Translation Inhibitor with Potent Activity Against Aggressive Non-Hodgkin Lymphomas

Midostaurin Shows Efficacy in Refractory Multiple Myeloma with TP53 Mutation and Elevated Expression of NTRK1, NTRK3 and AURKA

External Stimuli Modulate EZH2 Expression in Chronic Lymphocytic Leukemia. Rationale and Evidence for Synergistic Anti-Tumor Effects of B Cell Signaling and EZH2 Inhibitors

Redundant JAK, SRC and PI3 Kinase Signaling Pathways Regulate Cell Survival in Human Ph-like ALL Cell Lines and Primary Cells

Megakaryocytic TGFβ1 Partitions Hematopoiesis into Amplifying Stem and Progenitor Cells and Maturing Effector Cells

Notch Signaling Controls Drug Response in B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Differential Impact of Signaling Inhibitor Treatment Versus Standard Chemoimmunotherapy on Chronic Lymphocytic Leukemia T Cells: Clinical Implications

Altered Peripheral Immune Phenotypes in Mantle Cell Lymphoma Survivors

Increased Risk of Toxicity with Novel PI3K Delta Inhibitor Combinations Compared with Standard Use in Non-Hodgkin Lymphoma Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only